focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 327.50
Bid: 326.00
Ask: 328.00
Change: 23.00 (7.55%)
Spread: 2.00 (0.613%)
Open: 307.00
High: 331.00
Low: 300.00
Prev. Close: 304.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pricing of senior notes

12 Apr 2024 07:00

RNS Number : 3607K
Synthomer PLC
12 April 2024
 

April 12, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

 

SYNTHOMER PLCPRICING OF SENIOR NOTES

Synthomer plc ("Synthomer") today announces that it has priced its offering (the "Offering") of €350 million in aggregate principal amount of senior notes due 2029 (the "Notes") at a coupon of 7⅜%.

The Notes will be unconditionally guaranteed by certain of Synthomer's subsidiaries. Synthomer intends to use the proceeds from this Offering, together with cash on balance sheet, to (i) repurchase or redeem certain of its existing 3⅞% senior notes due 2025 (the "Existing Notes") and (ii) pay certain costs, expenses and fees relating to the Offering.

The Offering is expected to close on or about April 18, 2024, subject to customary conditions precedent for similar transactions.

Lily Liu, Synthomer plc Chief Financial Officer, commented: "We are very pleased with the substantial support for this transaction, which represents another major milestone in improving our financial platform, and puts Synthomer in a stronger position to deliver our strategy."

 

 

Cautionary Statement

The Offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

The Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes are being offered and sold in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act.

Promotion of the Notes in the United Kingdom is restricted by the Financial Services and Markets Act 2000 (the "FSMA"), and accordingly, the Notes are not being promoted to the general public in the United Kingdom. This announcement is only addressed to and directed at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments (being investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (iii) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Financial Promotion Order, or (iv) to the extent that doing so does not prejudice the lawful distribution of the announcement to the foregoing, are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any Notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). The Notes will only be available to relevant persons and this announcement must not be acted on or relied on by anyone who is not a relevant person. No key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "EUWA") (the "UK PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the UK has been prepared and, therefore, offering or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. Any offer of the Notes in the UK will be made pursuant to an exemption under Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA from a requirement to publish a prospectus for offers of securities.

This announcement does not constitute and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer within the meaning of the Regulation (EU) 2017/1129 (as amended), and any relevant implementing measure in the relevant Member State of the European Economic Area (the "Prospectus Regulation"). The offer and sale of the Notes will be made pursuant to an exemption under the Prospectus Directive, as implemented in Member States of the European Economic Area, from the requirement to produce a prospectus for offers of securities.

Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA.

This press release may include "forward looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward looking statements include all matters that are not historical facts and include statements regarding Synthomer or its affiliates' intentions, beliefs or current expectations concerning, among other things, the Offering.

By their nature, forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward looking statements are not guarantees of future performance and that Synthomer and its affiliates' actual results of operations, financial condition and liquidity, and the development of the industry in which they operate may differ materially from those made in or suggested by the forward looking statements contained in this press release. In addition, even if Synthomer or its affiliates' results of operations, financial condition and liquidity, and the development of the industry in which the Synthomer operates are consistent with the forward looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you should not rely on forward looking statements as a prediction of actual results.

Statements of intent in this press release shall not constitute a notice of redemption under the indenture governing Synthomer's 3⅞% senior notes due 2025. Any such notice, if made, will only be made in accordance with the provisions of the relevant indenture.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODDBGDSUBBDGSB
Date   Source Headline
5th Aug 202211:27 amRNSDirector/PDMR Shareholding
4th Aug 20222:57 pmRNSDirector/PDMR Shareholding
4th Aug 20222:35 pmRNSDirector/PDMR Shareholding
3rd Aug 202212:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSResults for the six months ended 30 June 2022
15th Jul 20222:32 pmRNSHolding(s) in Company
8th Jul 202210:23 amRNSHolding(s) in Company
1st Jul 20227:00 amRNSChief Financial Officer
30th Jun 20225:04 pmRNSHolding(s) in Company
21st Jun 20227:00 amRNSAppointment of Non-Executive Director
17th May 202212:55 pmRNSHolding(s) in Company
5th May 202212:39 pmRNSHolding(s) in Company
4th May 20224:46 pmRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSAppointment of Joint Corporate Brokers
28th Apr 202212:24 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 2022 trading update
26th Apr 20229:33 amRNSHolding(s) in Company
20th Apr 20224:13 pmRNSHolding(s) in Company
5th Apr 20224:18 pmRNSDirector/PDMR Shareholding
1st Apr 20221:34 pmRNSCompletion of adhesives acquisition
29th Mar 20223:17 pmRNSHolding(s) in Company
29th Mar 20223:14 pmRNSDirector/PDMR Shareholding
25th Mar 20222:03 pmRNSAnnual Financial Report
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:48 pmRNSDirector/PDMR Shareholding
14th Mar 20229:35 amRNSHolding(s) in Company
9th Mar 202212:52 pmRNSDirector/PDMR Shareholding
8th Mar 20223:22 pmRNSDirector/PDMR Shareholding
8th Mar 20223:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSPreliminary Results for the year ended 31 Dec 2021
14th Feb 20227:00 amRNSPre-close trading update
10th Feb 20223:10 pmRNSNOTIFICATION OF MAJOR HOLDINGS
22nd Dec 20215:10 pmRNSDirector/PDMR Shareholding
21st Dec 20213:09 pmRNSDirector/PDMR Shareholding
20th Dec 20213:40 pmRNSDirector/PDMR Shareholding
17th Dec 202112:29 pmRNSResults of General Meeting
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration
11th Nov 20212:24 pmRNSDirector/PDMR Shareholding
4th Nov 20212:11 pmRNSDirector/PDMR Shareholding
1st Nov 20217:00 amRNSNew Chief Executive
28th Oct 20213:17 pmRNSResult of Placing
28th Oct 20217:00 amRNSAcquisition
28th Oct 20217:00 amRNSPROPOSED PLACING OF NEW ORDINARY SHARES
30th Sep 20213:08 pmRNSDirectorate Change
10th Sep 20218:23 amRNSDirector Declaration
5th Aug 20217:01 amRNSBoard Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.